Identification of a serotonin/glutamate receptor complex implicated in psychosis
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The psychosis associated with schizophrenia is characterized by alterations in sensory processing and perception. Some antipsychotic drugs were identified by their high affinity for serotonin 5-HT2A receptors (2AR). Drugs that interact with metabotropic glutamate receptors (mGluR) also have potential for the treatment of schizophrenia. The effects of hallucinogenic drugs, such as psilocybin and lysergic acid diethylamide, require the 2AR and resemble some of the core symptoms of schizophrenia. Here we show that the mGluR2 interacts through specific transmembrane helix domains with the 2AR, a member of an unrelated G-protein-coupled receptor family, to form functional complexes in brain cortex. The 2AR-mGluR2 complex triggers unique cellular responses when targeted by hallucinogenic drugs, and activation of mGluR2 abolishes hallucinogen-specific signalling and behavioural responses. In post-mortem human brain from untreated schizophrenic subjects, the 2AR is upregulated and the mGluR2 is downregulated, a pattern that could predispose to psychosis. These regulatory changes indicate that the 2AR-mGluR2 complex may be involved in the altered cortical processes of schizophrenia, and this complex is therefore a promising new target for the treatment of psychosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the 5HT2A receptor forms a functional heterodimer with the mGluR2 receptor, which evokes allosteric effects on serotonin agonist binding [34];”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“this interaction reduces the hallucinogen-specific Gi/o protein signaling and behavior and may account for the lack of hallucinogenic action of 2-bromo-LSD (5) noted above.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Temporal pattern encoding relieves the cellular information bottleneck, where many stimuli must signal through few intracellular pathways to generate diverse and specific cellular responses (30 -32) but complicates the relationship between synthetic target modulators and their cellular and clinical effects.”
From Cytokine Response Is Determined by Duration of Receptor and Signal Transducers and Activators of Transcription 3 (STAT3) Activation (2013) · cites this paper as [31]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several recent studies of drugs acting at cell surface receptor targets show that the activation mechanisms responsible for their cellular and systemic effects are more complex than accounted for by their classical pharmacological profiles (30 -32).”
From Cytokine Response Is Determined by Duration of Receptor and Signal Transducers and Activators of Transcription 3 (STAT3) Activation (2013) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Basic local alignment search tool
Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990) · Journal of Molecular Biology · doi:10.1006/jmbi.1990.9999 · Cited by 98,669
Thompson, J. D., Higgins, D. G., & Gibson, T. J. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.22.4673 · Cited by 64,617
Comparative Protein Modelling by Satisfaction of Spatial Restraints
Šali, A., & Blundell, T. L. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1626 · Cited by 12,977
Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637
High-Resolution Crystal Structure of an Engineered Human β 2 -Adrenergic G Protein–Coupled Receptor
Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G. F., Thian, F. S., Kobilka, T. S., Choi, H.-J., Kuhn, P., Weis, W. I., Kobilka, B. K., et al. (2007) · Science · doi:10.1126/science.1150577 · Cited by 3,264
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Self-citation
Cited by
Items 101–200 of 835
Fazio, F., Lionetto, L., Curto, M., Iacovelli, L., Cavallari, M., Zappulla, C., Ulivieri, M., Napoletano, F., Capi, M., Corigliano, V., et al. (2015) · Scientific Reports · doi:10.1038/srep17799 · Cited by 121
“The evidence that mGlu2 receptors negatively regulate responses mediated by 5-HT 2A receptors 17,18 paved the way for the development of mGlu2/3 receptor agonists or mGlu2 receptor positive allosteric modulators (PAMs) in the treatment of schizophrenia.”
BackgroundAn update on the physiological and therapeutic relevance of GPCR oligomers
Farran, B. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.008 · Cited by 115
Pharmacology of Free Fatty Acid Receptors and Their Allosteric Modulators
Grundmann, M., Bender, E., Schamberger, J., & Eitner, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041763 · Cited by 120
“Heteromeric GPCR complexes are increasingly thought to further shape GPCR signaling, such as adenosine A2a-A1 or A2a-D2 [9,10], D1-D3 dopamine [11] chemokine CXCR2, and δ-opioid receptors [12] or angiotensin II AT1-F2α prostanoid receptors [13], to give only few examFigure 1.”
BackgroundCussac, D., Boutet-Robinet, E. A., Ailhaud, M., Newman‐Tancredi, A., Martel, J., Danty, N., & Rauly‐Lestienne, I. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.07.040 · Cited by 124
“, 2003, 2007, see Nichols 2004 for review), although other receptors may play a role (Nichols, 2004; González-Maeso et al., 2008).”
BackgroundRediger, A., Piechowski, C. L., Yi, C.-X., Tarnow, P., Strotmann, R., Grüters, A., Krude, H., Schöneberg, T., Tschöp, M. H., Kleinau, G., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.287607 · Cited by 111
Functional crosstalk between GPCRs: with or without oligomerization
Prézeau, L., Rives, M., Comps‐Agrar, L., Maurel, D., Kniazeff, J., & Pin, J. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.10.009 · Cited by 119
“The mechanism of this complex crosstalk is not well understood yet, but has been proposed to be the result of mGlu2–5-HT2A receptor oligomerization in cortical neurons where they colocalize and coimmunoprecipitate [35 ].”
BackgroundMethodInfluentialCurrent status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors
Aloyo, V. J., Berg, K. A., Spampinato, U., Clarke, W. P., & Harvey, J. A. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.010 · Cited by 116
Matrisciano, F., Tueting, P., Maccari, S., Nicoletti, F., & Guidotti, A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.274 · Cited by 110
Cortical Plasticity, Excitatory–Inhibitory Balance, and Sensory Perception
Carcea, I., & Froemke, R. C. (2013) · Progress in Brain Research · doi:10.1016/b978-0-444-63327-9.00003-5 · Cited by 110
“As with dopamine, serotonin and its receptors appear to play an important role in the generation of perceptual psychotic episodes in schizophrenia and following the use of psychedelic drugs (Gonzalez-Maeso et al., 2008; Lesch and Waider, 2012).”
Metabotropic glutamate receptors and the control of chronic pain
Chiechio, S., & Nicoletti, F. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.10.010 · Cited by 112
Classical hallucinogens and neuroimaging: A systematic review of human studies
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.026 · Cited by 107
“…neurotrophic factor [GDNF], thus enhancing neuroplasticity and neurogenesis by increasing the size of dendritic spines on cortical neurons (González-Maeso et al., 2008; Vollenweider and Kometer, 2010; Moreno et al., 2011, 2013; Hanks and González-Maeso, 2013; Baumeister et al., 2014;…”
Winstock, A. R., Kaar, S., & Borschmann, R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113513852 · Cited by 104
“, 2008), contributing to the theory that the 5HT2a and metabotropic glutamate systems might be involved in the disturbed cortical processes found in schizophrenia (González-Maeso et al., 2008).”
BackgroundThe oligomeric state sets GABAB receptor signalling efficacy
Comps‐Agrar, L., Kniazeff, J., Nørskov-Lauritsen, L., Maurel, D., Gassmann, M., Gregor, N., Prézeau, L., Bettler, B., Durroux, T., Trinquet, E., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.143 · Cited by 119
“…Moniri et al, 2004; Galandrin et al, 2007) and (ii) to form dimers or even larger oligomeric complexes, offering new possible synergistic re- ceptor responses (Terrillon and Bouvier, 2004; Carriba et al, 2008; Gonzalez-Maeso et al, 2008; Gurevich and Gurevich, 2008; Panetta and Greenwood, 2008).”
BackgroundFunctional dynamics of G protein-coupled receptors reveal new routes for drug discovery
Conflitti, P., Lyman, E. R., Sansom, M. S. P., Hildebrand, P. W., Gutiérrez‐de‐Terán, H., Carloni, P., Ansell, T. B., Yuan, S., Barth, P., Robinson, A. S., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01083-3 · Cited by 120
“Conversely, in patients affected by schizophrenia, formation of the complex composed of 5-HT 2A R and mGlu 2 R is hampered by upregulation of 5-HT 2A R and downregulation of mGlu 2 R 282 .”
Fuxé, K., Borroto‐Escuela, D. O., Romero‐Fernandez, W., Palkovits, M., Tarakanov, A. O., Ciruela, F., & Agnati, L. F. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.242 · Cited by 110
“…produce their potential antipsychotic effects by targeting the mGlu2-5-HT2A heteroreceptor complex most likely located in distinct pyramidal and granular cells and reduce the hallucinogenspecific Gi/o signaling via allosteric interactions over the receptor interface (Gonzalez-Maeso et al, 2008).”
BackgroundInfluentialShan, J., Khelashvili, G., Mondal, S., Mehler, E. L., & Weinstein, H. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002473 · Cited by 105
“[26,27,28,29,30,31].”
The Prevalence, Maintenance, and Relevance of G Protein–Coupled Receptor Oligomerization
Milligan, G. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.084780 · Cited by 112
“A key element of the studies by González-Maeso et al. (2008), which was extended by further studies by Fribourg et al. (2011), was the alteration in signal transduction pathways produced via this heteromer.”
BackgroundSelf-citationPharmacology of Hallucinations: Several Mechanisms for One Single Symptom?
Rolland, B., Jardri, R., Amad, A., Thomas, P., Cottencin, O., & Bordet, R. (2014) · BioMed Research International · doi:10.1155/2014/307106 · Cited by 113
“Recent work has shown that the action of psychedelic drugs on 5HT2ARs requires the indispensable formation of a complex between 5HT2AR and the metabotrop-ic glutamatergic mGlu2 receptor (mGlu2R) [55].”
BackgroundGPCRs: Lipid-Dependent Membrane Receptors That Act as Drug Targets
Chattopadhyay, A. (2014) · Advances in Biology · doi:10.1155/2014/143023 · Cited by 112
“GPCR oligomerization facilitates an increased crosstalk between receptors via homo- and/or heterodimers as well as higherorder oligomers [112, 115, 117].”
BackgroundDual agonist occupancy of AT1-R–α2C-AR heterodimers results in atypical Gs-PKA signaling
Bellot, M., Galandrin, S., Boularan, C., Matthies, H. J. G., Despas, F., Denis, C., Javitch, J. A., Mazères, S., Sanni, S. J., Pons, V., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1766 · Cited by 110
Blough, B. E., Landavazo, A., Decker, A. M., Partilla, J. S., Baumann, M. H., & Rothman, R. B. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3557-7 · Cited by 101
“Additional reports have implicated a 5-HT2A-metabotropic glutamate 2 receptor (5-HT2A-mGluR2) heterodimeric complex as being responsible for a unique hallucinogen-specific downstream signaling pattern, but more studies are warranted in order to fully understand the biological role of this complex (Delille et al. 2012;…”
BackgroundKometer, M., Cahn, B. R., Andel, D., Carter, O. L., & Vollenweider, F. X. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.10.002 · Cited by 109
“cinations in Parkinson’s (6 – 8) and schizophrenic patients (9).”
BackgroundAznar, S., & Hervig, M. E.-S. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.02.008 · Cited by 108
Borroto‐Escuela, D. O., Romero‐Fernandez, W., Tarakanov, A. O., Marcellino, D. J., Ciruela, F., Agnati, L. F., & Fuxé, K. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.09.110 · Cited by 111
“Ciruela), luigiagnati@ hallucinogens of the indolalkylamine type [8,9].”
BackgroundAntipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects
Ibi, D., Revenga, M. D. L. F., Kezunovic, N., Muguruza, C., Saunders, J. M., Gaitonde, S. A., Moreno, J. L., Ijaz, M. K., Santosh, V., Kozlenkov, A., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4616 · Cited by 109
Self-citationWard, R. J., Pediani, J. D., & Milligan, G. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.287649 · Cited by 99
Self-citationFazio, F., Lionetto, L., Curto, M., Iacovelli, L., Copeland, C. S., Neale, S. A., Bruno, V., Battaglia, G., Salt, T. E., & Nicoletti, F. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.06.020 · Cited by 104
Structural and Biophysical Mechanisms of Class C G Protein-Coupled Receptor Function
Ellaithy, A., González‐Maeso, J., Logothetis, D. E., & Levitz, J. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.07.008 · Cited by 106
Self-citationKargl, J., Balenga, N. A. B., Parzmair, G. P., Brown, A. J., Heinemann, Á., & Waldhoer, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.364109 · Cited by 111
Menna, L. D., Joffe, M. E., Iacovelli, L., Orlando, R., Lindsley, C. W., Mairesse, J., Gressèns, P., Cannella, M., Caraci, F., Copani, A., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.026 · Cited by 102
Rawani, N. S., Chan, A. W., Dursun, S. M., & Baker, G. B. (2024) · Antioxidants · doi:10.3390/antiox13060709 · Cited by 113
“Gonzalez-Maeso et al. [36] proposed that these hallucinogenic drugs can interact with both glutamate and serotonin receptors at what has been proposed as the 5-HT2AR/mGluR2 complex.”
BackgroundInfluentialHeterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades
Delille, H. K., Becker, J. M., Burkhardt, S., Bleher, B., Terstappen, G. C., Schmidt, M. U., Meyer, A. H., Unger, L., Marek, G. J., & Mezler, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.010 · Cited by 104
“…in layer V pyramidal cells in mPFC (Marek et al., 2000) and treatment of mice with the mGlu 2/3 agonist LY379268 or the mGlu 2 enhancer LY566332 attenuated stimulation of PI hydrolysis in the frontal cortex induced by 5-HT 2A activation with DOI (Gonzalez-Maeso et al., 2008; Molinaro et al., 2009).”
InfluentialGhose, S., Gleason, K. A., Potts, B. W., Lewis-Amezcua, K., & Tamminga, C. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.08091445 · Cited by 96
“The lack of effect of diagnosis on mGluR2 expression reflects normal levels of mGluR2 protein and is consistent with our previous study showing unchanged levels of mGluR2 mRNA in the grey matter of the DLPFC in schizophrenia (17) but differs from a recent report in small cohort of 7 pairs of medication-free cases of s…”
BackgroundResultSerotonergic Mechanisms as Targets for Existing and Novel Antipsychotics
Meltzer, H. Y. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_4 · Cited by 104
Targeting glutamate synapses in schizophrenia
Field, J. R., Walker, A. G., & Conn, P. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.08.004 · Cited by 106
Navarro, G., Varani, K., Lillo, A., Vincenzi, F., Rivas‐Santisteban, R., Raïch, I., Reyes‐Resina, I., Ferreiro‐Vera, C., Borea, P. A., de Medina, V. S., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104940 · Cited by 102
de Bartolomeis, A., Vellucci, L., Barone, A., Manchia, M., Luca, V. D., Iasevoli, F., & Correll, C. U. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108236 · Cited by 98
GPCR homomers and heteromers: A better choice as targets for drug development than GPCR monomers?
Casadó, V., Cortés, A., Mallol, J., Pérez‐Capote, K., Ferré, S., Lluís, C., Franco, R., & Canela, E. I. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.07.005 · Cited by 93
“For 5- HT2A-mGlu2 receptor heteromers (González-Maeso et al., 2008), both the ligand binding modulation and heteromerization is altered with specific mutated or chimeric receptors.”
BackgroundPhysiological relevance of GPCR oligomerization and its impact on drug discovery
Panetta, R., & Greenwood, M. T. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.09.002 · Cited by 92
“Neuropsychopharmacology 32, 2249–2259 63 Gonzalez-Maeso, J. et al. (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis.”
BackgroundInfluentialPershing, M. L., Bortz, D. M., Pocivavsek, A., Fredericks, P. J., Jørgensen, C. V., Vunck, S. A., Leuner, B., Schwarcz, R., & Bruno, J. P. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.017 · Cited by 88
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript with clinical reports (Bullock et al., 2008; Freedman, 1995; Gonzalez-Maeso et al., 2008), though exceptions have been noted (DeLuca et al., 2006; Ghose et al., 2009).”
MethodMetabotropic glutamate receptors as therapeutic targets for schizophrenia
Vinson, P. N., & Conn, P. J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.005 · Cited by 108
“In addition, there is evidence from a molecular standpoint that the two receptor types are colocalized in the cortex and are jointly implicated in the neuropathology of schizophrenia (Gonzalez-Maeso et al., 2008).”
BackgroundFell, M. J., McKinzie, D. L., Monn, J. A., & Svensson, K. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.06.007 · Cited by 97
“…and mGlu2 receptors were reported to form functional heterodimers in the cortex involving the 4th and 5th transmembrane domain of mGlu2 receptors (Gonzalez-Maeso et al., 2008); within this complex, activation of mGlu2 receptors specifically inhibits egr-2 expression, a major signaling pathway…”
BackgroundInfluentialEstrogens and SERMS as adjunctive treatments for schizophrenia
Kulkarni, J., Butler, S., & Riecher‐Rössler, A. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.03.002 · Cited by 96
Popova, N. K., Tsybko, A. S., & Naumenko, V. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158814 · Cited by 96
Instability of a Class A G Protein-Coupled Receptor Oligomer Interface
Fonseca, J. M., & Lambert, N. A. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.053876 · Cited by 90
“This stabilization required the presence in both C-D2R and D2R-V of a cysteine residue in transmembrane domain 4 (TM4), a region identified as a putative oligomer interface in these and other class A GPCRs.”
BackgroundInfluentialde Bartolomeis, A., Buonaguro, E. F., & Iasevoli, F. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2921-8 · Cited by 89
“…interactions in schizophrenia pathophysiology and pharmacotherapy: (1) It has been reported that metabotropic glutamate receptor (mGluRs) may interact physically with 5-HT 2A receptors (Gonzalez-Maeso et al. 2008) and both receptors could be valuable targets for antipsychotic compounds.”
BackgroundMeinhardt, M. W., Pfarr, S., Fouquet, G., Rohleder, C., Meinhardt, M. L., Barroso-Flores, J., Hoffmann, R., Jeanblanc, J., Paul, E., Wagner, K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh2399 · Cited by 89
Heterodimerization of human apelin and kappa opioid receptors: Roles in signal transduction
Li, Y., Chen, J., Bai, B., Du, H., YouWang, L., & Liu, H. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.12.012 · Cited by 89
G protein-coupled receptor dimers: Functional consequences, disease states and drug targets
Dalrymple, M. B., Pfleger, K. D. G., & Eidne, K. A. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.03.004 · Cited by 102
“A collaborative effort amongst several research groups assessed the potential interactions of GPCRs within the cerebral cortex using a combination of BRET, FRET and co-immunoprecipitation methodologies, clearly demonstrating that the 5-HT2a receptor and mGluR2 formed functional heterodimeric complexes with a distinct…”
BackgroundStructural biology of GABAB receptor
Frangaj, A., & Fan, Q. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.011 · Cited by 95
“, 2001), they have recently been discovered to assemble into heterodimers with other class C and class A GPCRs (Doumazane et al., 2011; Gama et al., 2001; Gonzalez-Maeso et al., 2008; Moreno Delgado et al., 2017; Pandya et al., 2016; Yin et al., 2014).”
Glutamate Receptor Abnormalities in Schizophrenia: Implications for Innovative Treatments
Rubio, M. D., Drummond, J. B., & Meador-Woodruff, J. H. (2012) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2012.20.1.001 · Cited by 83
“…in schizophrenia (Crook et al., 2002; Ghose et al., 2008), while transcript level studies have produced confl icting results, showing an increase in the white matter of the prefrontal cortex or a decrease in mGluR2 expression in this same area (Ghose et al., 2008; Gonzalez-Maeso et al., 2008).”
ResultGPCR oligomers in pharmacology and signaling
González‐Maeso, J. (2011) · Molecular Brain · doi:10.1186/1756-6606-4-20 · Cited by 98
“provided the basis to identify the specific mGlu2 receptor TM domains responsible for GPCR heterocomplex formation [34].”
BackgroundInfluentialSelf-citationCanals, M., & Milligan, G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710300200 · Cited by 86
Self-citationCottet, M., Faklaris, O., Maurel, D., Scholler, P., Doumazane, E., Trinquet, E., Pin, J., & Durroux, T. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00092 · Cited by 105
“Hetero-oligomerization in vivo has also been suspected for various GPCR pairs although direct interactions between receptors were not formally demonstrated (González-Maeso et al., 2008; Albizu et al., 2011).”
BackgroundDysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects
Muguruza, C., Moreno, J. L., Umali, A., Callado, L. F., Meana, J. J., & González-Maeso, J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.10.006 · Cited by 85
“Mouse brain samples Experiments were performed on adult (8–12 weeks old) 5-HT2AR knockout (KO) and wildtype male 129S6/Sv mice (Gonzalez-Maeso et al. 2008).”
BackgroundMethodResultSelf-citationThe HIV Antiretroviral Drug Efavirenz has LSD-Like Properties
Gatch, M. B., Kozlenkov, A., Huang, R.-Q., Yang, W., Nguyen, J. D., González‐Maeso, J., Rice, K. C., France, C. P., Dillon, G. H., Forster, M. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.135 · Cited by 97
Self-citationMetabotropic glutamatergic receptors and their ligands in drug addiction
Pomierny-Chamioło, L., Rup, K., Pomierny, B., Niedzielska, E., Kalivas, P. W., & Filip, M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.012 · Cited by 80
Perez‐Aguilar, J. M., Shan, J., Levine, M. V., Khelashvili, G., & Weinstein, H. (2014) · Journal of the American Chemical Society · doi:10.1021/ja508394x · Cited by 87
Duan, W., Cao, D., Wang, S., & Cheng, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00375 · Cited by 85
Serotonin 2A receptor antagonists for treatment of schizophrenia
Ebdrup, B. H., Rasmussen, H., Arnt, J., & Glenthøj, B. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.601738 · Cited by 82
“3 Post-mortem studies of 5-HT2A receptors in schizophrenia Eleven [20-30] of sixteen [31-35] post-mortem studies of brain tissue from schizophrenia patients have reported a decreased 5-HT2A receptor expression in cortical areas.”
BackgroundDynamics and modulation of metabotropic glutamate receptors
Rondard, P., & Pin, J. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.12.001 · Cited by 95
Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway
Ibarra‐Lecue, I., Mollinedo-Gajate, I., Meana, J. J., Callado, L. F., Díez-Alarcia, R., & Urigüen, L. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0076-y · Cited by 93
“The activation of all these Neuropsychopharmacology (2018) 0:1 – 8 Gα-proteins was antagonized in the presence of ketanserin (10 μM) (data not shown).”
BackgroundMethodInfluentialSelf-citationKaraki, S., Becamel, C., Murat, S., Mannoury la Cour, C., Millan, M. J., Prézeau, L., Bockaert, J., Marin, P., & Vandermoere, F. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.036558 · Cited by 74
Lopez-Gil, X., Artigas, F., & Adell, A. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361416 · Cited by 77
Carli, M., & Invernizzi, R. W. (2014) · Frontiers in Neural Circuits · doi:10.3389/fncir.2014.00058 · Cited by 74
“The causes for the lack of effect of this D2/D3 antagonist are not clear and may depend on various factors such as whether emitting a perseverative responses leads to behavioral consequence or not, brain area or else; for example it has been repeatedly shown that similar pharmacological manipulations increase persever…”
BackgroundInfluentialLi, W., Jin, J., Xiong, T., Yu, P., & Mao, L. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202204134 · Cited by 85
Pitychoutis, P. M., Belmer, A., Moutkine, I., Adrien, J., & Maroteaux, L. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.126 · Cited by 80
New concepts in calcium‐sensing receptor pharmacology and signalling
Ward, D. T., & Riccardi, D. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01511.x · Cited by 79
“new potential drug targets for psychosis (Gonzalez-Maeso et al., 2008).”
BackgroundFanelli, F., & Benedetti, P. G. D. (2011) · Chemical Reviews · doi:10.1021/cr100437t · Cited by 82
Class A GPCR heterodimers: evidence from binding studies
Birdsall, N. J. M. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.08.003 · Cited by 77
Allosteric control of an asymmetric transduction in a G protein-coupled receptor heterodimer
Liu, J., Zhang, Z., Moreno‐Delgado, D., Dalton, J. A. R., Rovira, X., Trapero, A., Goudet, C., Llebaria, A., Giraldo, J., Yuan, Q., et al. (2017) · eLife · doi:10.7554/elife.26985 · Cited by 80
“Understanding how a receptor can control the activity of its partner (González-Maeso et al., 2008; Albizu et al., 2010; Fribourg et al., 2011; Vilardaga et al., 2008; Han et al., 2009) will certainly help clarify this important issue, opening ways to control the function of GPCR heteromers.”
BackgroundCarbonaro, T. M., Eshleman, A. J., Forster, M. J., Cheng, K., Rice, K. C., & Gatch, M. B. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3658-3 · Cited by 66
“It has been suggested that the heteroreceptors induce a hallucinogenspecific second messenger cascade (Gonzalez-Maeso et al. 2008; Gonzalez-Maeso et al. 2007), although this has not been definitely established (Delille et al.”
G protein-coupled receptor heteromers are key players in substance use disorder
Derouiche, L., & Massotte, D. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.09.026 · Cited by 77
Making Structural Sense of Dimerization Interfaces of Delta Opioid Receptor Homodimers
Johnston, J. M., Aburi, M., Provasi, D., Bortolato, A., Urizar, E., Lambert, N. A., Javitch, J. A., & Filizola, M. (2011) · Biochemistry · doi:10.1021/bi101474v · Cited by 84
“In accordance with predictions from correlated mutation analysis of ORs (53, 54), and with published experimental evidence for several GPCR dimers and/or oligomers (19-31), we first focused on the TM4 andTM5 interfaces.”
BackgroundSelf-citationLi, M.-L., Hu, X., Li, F., & Gao, W. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.02.012 · Cited by 84
Stebelska, K. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31828741a5 · Cited by 86
Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia
Dogra, S., & Conn, P. J. (2022) · Molecular Pharmacology · doi:10.1124/molpharm.121.000460 · Cited by 79
Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis
Fuxé, K., Marcellino, D. J., Leo, G., & Agnati, L. F. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.10.010 · Cited by 75
“The heterodimer receptor interface among class A GPCRs also seems to involve some transmembrane domains, see [21 ,29].”
BackgroundRiga, M. S., Soria, G., Tudela, R., Artigas, F., & Celada, P. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000261 · Cited by 72
“5-HT2A-R and mGluR2/3 have been shown to form functional heterodimers that may be sensitive to the action of hallucinogens (Gonzalez-Maeso et al., 2008).”
BackgroundLambert, N. A. (2010) · Science Signaling · doi:10.1126/scisignal.3115pe12 · Cited by 71
Kulkarni, J., Hayes, E., & Gavrilidis, E. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328350360e · Cited by 81
Dopamine D2–D3 receptor heteromers: pharmacological properties and therapeutic significance
Maggio, R., & Millan, M. J. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.10.001 · Cited by 73
Role for serotonin2A (5-HT2A) and 2C (5-HT2C) receptors in experimental absence seizures
Venzi, M., David, F., Bellet, J., Cavaccini, A., Bombardi, C., Crunelli, V., & Giovanni, G. D. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.016 · Cited by 78
Bruno, V., Caraci, F., Copani, A., Matrisciano, F., Nicoletti, F., & Battaglia, G. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.044 · Cited by 79
Psychedelic‐inspired approaches for treating neurodegenerative disorders
Saeger, H. N., & Olson, D. E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15544 · Cited by 74
Serotonergic hallucinogens as translational models relevant to schizophrenia
Halberstadt, A. L., & Geyer, M. A. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000722 · Cited by 67
Adams, W. K., Kusljic, S., & van den Buuse, M. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.035 · Cited by 76
Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment
Ellaithy, A., Younkin, J., González‐Maeso, J., & Logothetis, D. E. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.06.002 · Cited by 80
Self-citationDelille, H. K., Mezler, M., & Marek, G. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.02.005 · Cited by 76
“Gonzalez-Maeso et al. presented several lines of evidence suggesting co-expression of mGlu2 and 5-HT2A in cortical cells (Fribourg et al., 2011; Gonzalez-Maeso et al., 2008).”
BackgroundMethodResultInfluentialDong, X., Li, Y.-C., Snyder, M. A., Gao, R. Y., Adelman, A. E., Zhang, W., Shumsky, J. S., & Gao, W. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.12 · Cited by 74
“To examine how this occurs, we first tested whether the effects involve protein-protein interactions because previous studies indicated that mGluRs could potentially interact with other receptor proteins (Enz, 2007; Gonzalez-Maeso et al , 2008).”
Zamberlan, F., Sanz, C., Martínez Vivot, R., Pallavicini, C., Erowid, F., Erowid, E., & Tagliazucchi, E. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00054 · Cited by 71
Therapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 80
“Indeed, as we deepen our understanding of various forms of functional selectivity including biased agonism [79], location bias [80], and GPCR crosstalk via heterodimerization [81], it becomes clear that psychedelics cannot be described simply as “ 5-HT2AR partial agonists.”
BackgroundPsychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches
Kantrowitz, J. T. (2020) · CNS Drugs · doi:10.1007/s40263-020-00752-2 · Cited by 72
Group III Metabotropic Glutamate Receptors: Pharmacology, Physiology and Therapeutic Potential
Mercier, M. S., & Lodge, D. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1415-y · Cited by 76
“Furthermore, a number of studies have demonstrated an antagonistinduced increase in evoked transmission, most often seen within the hypothalamus [114] [125] [138] [179], but also in other areas of the CNS, such as the amygdala [180], hippocampus [181] and spinal cord [182] [183], and tonically active group III mGlu re…”
BackgroundInfluentialKlein, A. B., Ultved, L., Adamsen, D., Santini, M. A., Tobeña, A., Fernández‐Teruel, A., Flores, P., Moreno, M., Cardona, D., Knudsen, G. M., et al. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2013.12.063 · Cited by 73
Muguruza, C., Miranda-Azpiazu, P., Díez-Alarcia, R., Morentin, B., González-Maeso, J., Callado, L. F., & Meana, J. J. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.08.009 · Cited by 69
Self-citationFunctional significance of serotonin receptor dimerization
Herrick‐Davis, K. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3622-1 · Cited by 71
Impairment of GABAB receptor dimer by endogenous 14‐3‐3ζ in chronic pain conditions
Laffray, S., Bouali‐Benazzouz, R., Papon, M.-A., Favereaux, A., Jiang, Y., Holm, T., Spriet, C., Desbarats, P., Fossat, P., Feuvre, Y. L., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.161 · Cited by 69
“Furthermore, changes in GPCR oligomerization are involved in pathophysiological conditions such as psychosis (Gonzalez-Maeso et al , 2008).”
Canal, C. E., Booth, R. G., & Morgan, D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.01.007 · Cited by 68
“Also, the 5-HT2C receptor may heterodimerize with 5-HT2A and/or other receptors that might impact the pharmacology of 5-HT2C ligands (Gonzalez-Maeso et al., 2008).”
Background
Metadata
- Authors
- González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., Gingrich, J. A., Filizola, M., Meana, J. J., & Sealfon, S. C.
- Affiliations
- University of the Basque Country (ES)
- University of Glasgow (GB)
- New York State Psychiatric Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Sealfon, Stuart C.
- ORCID
- Venue
- Nature
- Published
- 2008-02-24
- Volume
- 452
- Issue
- 7183
- Pages
- 93-97
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2743172
- OpenAlex
- W2024942419
- Cited by
- 803
- References
- 44
- Citations by year
- 2026: 18 · 2025: 21 · 2024: 23 · 2023: 34 · 2022: 44 · 2021: 38 · 2020: 36 · 2019: 33 · 2018: 45 · 2017: 44 · 2016: 51 · 2015: 37 · 2014: 52 · 2013: 62 · 2012: 71
- FWCI
- 27.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- National Institute of Mental Health (U01MH083545)
- National Institute on Drug Abuse (T32DA007135, P01DA012923)
- National Institute of General Medical Sciences (T32GM062754)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- 5-HT2A receptor, mGluR2, metabotropic glutamate receptors, receptor complex, schizophrenia, psychosis, hallucinogens, LSD, psilocybin, cortical dysfunction, antipsychotic drug targets, postmortem brain
- MeSH terms
- Animals, Brain, Cell Line, Cells, Cultured, Hallucinogens, Humans, Models, Molecular, Protein Binding, Psychotic Disorders, Schizophrenia, Signal Transduction, Down-Regulation, Up-Regulation, Protein Structure, Tertiary, Receptors, Metabotropic Glutamate, Receptor, Serotonin, 5-HT2A, Multiprotein Complexes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.